Investigation of Carbonic Anhydrase Inhibitory Potency of (Z/E)-Alkyl N'-benzyl-N-(arylsulfonyl)-carbamimidothioates

Future Medicinal Chemistry 2023
Morteza Abdoli, Viviana De Luca, Clemente Capasso, Claudiu T. Supuran, Raivis Žalubovskis

Aim: Among 15 human (h) carbonic anhydrase (CA; EC 4.2.1.1) isoforms, two (hCA IX and XII) play important roles in the growth and survival of tumor cells, making them therapeutic targets for cancer treatment. This study aimed to develop novel sulfonamide-based compounds as selective hCA IX and XII inhibitors. Materials & methods: A library of novel N-sulfonyl carbamimidothioates was obtained for CA inhibitory activity studies against four hCA isoforms. Results: None of the developed compounds displayed inhibitory potential against off-target isoforms hCA I and II. However, they effectively inhibited tumor-associated hCA IX and XII. Conclusion: The present study suggests potent lead compounds as selective hCA IX and XII inhibitors with anticancer activity.

Atslēgas vārdi
(Z/E)-alkyl N'-benzyl-N-(arylsulfonyl)-carbamimidothioates | antitumor | carbonic anhydrase | inhibitors | sulfonamides
DOI
10.4155/fmc-2022-0287
Hipersaite
https://www.future-science.com/doi/10.4155/fmc-2022-0287

Abdoli, M., De Luca, V., Capasso, C., Supuran, C., Žalubovskis, R. Investigation of Carbonic Anhydrase Inhibitory Potency of (Z/E)-Alkyl N'-benzyl-N-(arylsulfonyl)-carbamimidothioates. Future Medicinal Chemistry, 2023, Vol. 15, No. 7, 615.-627.lpp. ISSN 1756-8919. e-ISSN 1756-8927. Pieejams: doi:10.4155/fmc-2022-0287

Publikācijas valoda
English (en)